Web4 apr. 2024 · Hepcludex. Werkzame stof. bulevirtide. Houder. Gilead Sciences Belgium B.V. Status. Lopend. Indicatie. behandeling van plasma‐ (of serum‐) HDV‐RNA‐positieve … Web14 sep. 2024 · Bulevirtide (Hepcludex ®; formerly Myrcludex B) is a first-in-class entry inhibitor developed by MYR GmbH for the treatment of chronic HDV and HBV infections [ …
Drug and Biologic Pipeline Update
Web21 mrt. 2024 · Posologie Le bulévirtide doit être administré à la dose de 2 mg une fois par jour (toutes les 24 h ± 4 h) par injection sous- cutanée, en monothérapie ou en co-administration avec un analogue nucléosidique/nucléotidique pour le traitement d'une infection sous-jacente par le VHB. WebMNP Hepcludex (bulevirtide) ‐ summarized information for publication – Vs. March 2024 Page 6 Informations résumées_Français Nom du médicament HEPCLUDEX 2 mg … or a hundred years song
Hepcludex European Medicines Agency
WebHepcludex 2 mg powder for solution for injection bulevirtide. This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You … WebHEPCLUDEX 2 mg powder for solution for injection Active Ingredient: bulevirtide acetate Company: Gilead Sciences Ltd See contact details ATC code: J05AX28 About Medicine … WebThe drug, which blocks the entry of the hepatitis B and hepatitis D virus into the liver cell, was approved by the European Commission on 31 July 2024 as a drug with the trade … or a and b